H.C. Wainwright Reiterates a Buy Rating on Synergy Pharmaceuticals Inc (SGYP)


H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Synergy Pharmaceuticals Inc (NASDAQ: SGYP) today and set a price target of $7. The company’s shares closed yesterday at $1.60, close to its 52-week low of $1.43.

According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.8% and a 34.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Synergy Pharmaceuticals Inc with a $9 average price target.

See today’s analyst top recommended stocks >>

Based on Synergy Pharmaceuticals Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $36.1 million. In comparison, last year the company had a GAAP net loss of $73.89 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Synergy Pharmaceuticals, Inc. engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.

Read More on SGYP:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts